Drugs / rPA vaccine
rPA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00170469 | Mar 2005 → Feb 2007 | anthrax infection | PharmAthene UK Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00170456 Comparator | Mar 2005 → Jan 2007 | anthrax infection | PharmAthene UK Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-03-12 | Altimmune, Inc. | Results Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program altimmune.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rPA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00170456 ↗ |
| Known as | Recombinant (rPA Based) Anthrax Vaccine | “A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine...” NCT00170469 ↗1“A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in...” NCT00170456 ↗ |
| Known as | Recombinant Anthrax Vaccine | “Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed” NCT00170469 ↗ |
| Modality | Vaccine | “rPA anthrax vaccine” NCT00170456 ↗ |